Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-up

Yalcin A. D., Gorczynski R. M., ÇİLLİ A., Strauss L.

CLINICAL LABORATORY, cilt.60, sa.9, ss.1561-1564, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 9
  • Basım Tarihi: 2014
  • Doi Numarası: 10.7754/clin.lab.2013.130302
  • Dergi Adı: CLINICAL LABORATORY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1561-1564
  • Anahtar Kelimeler: omalizumab, severe persistent allergic asthma, type-2 diabetes, high blood glucose level, side effect, sucrose, pulmonary function test (FEV1/FVC rates), exhaled nitric oxide concentrations (FeNO), asthma control test (ACT), Anti-IgE, ECP (eosinophilic cationic peptid), high sensitive CRP (hs-CRP), QUALITY-OF-LIFE, MONOCLONAL-ANTIBODY, NITRIC-OXIDE
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: Therapeutic anti-IgE antibodies (Xolair, omalizumab) able to reduce free IgE levels and to block the binding of IgE to Fcepsilon RI without cross-linking IgE and triggering degranulation of IgE-sensitised cells have been developed.